SON-1010

· Sonnet BioTherapeutics

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for SON-1010, covering 2026-02-03 to 2026-02-03. Get the full timeline:

Most recent: Clinical Trial Update: Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer [Phase 1, Phase 2]

See pricing